TrialThe oncologist2024

The ASCENT Trial: a phase 2 study of induction and consolidation afatinib and chemoradiation with or without surgery in stage III EGFR-mutant NSCLC.

Allison E B Chang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.